Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) EBITDA Margin (2022 - 2025)

Stoke Therapeutics has reported EBITDA Margin over the past 4 years, most recently at 4125.32% for Q4 2025.

  • Quarterly results put EBITDA Margin at 4125.32% for Q4 2025, down 407757.0% from a year ago — trailing twelve months through Dec 2025 was 3.36% (up 24041.0% YoY), and the annual figure for FY2025 was 3.36%, up 24041.0%.
  • EBITDA Margin for Q4 2025 was 4125.32% at Stoke Therapeutics, down from 357.38% in the prior quarter.
  • Over the last five years, EBITDA Margin for STOK hit a ceiling of 71.22% in Q1 2025 and a floor of 4125.32% in Q4 2025.
  • Median EBITDA Margin over the past 4 years was 679.94% (2023), compared with a mean of 810.6%.
  • Biggest five-year swings in EBITDA Margin: surged 90996bps in 2024 and later crashed -407757bps in 2025.
  • Stoke Therapeutics' EBITDA Margin stood at 768.88% in 2022, then fell by -25bps to 957.71% in 2023, then soared by 95bps to 47.75% in 2024, then plummeted by -8539bps to 4125.32% in 2025.
  • The last three reported values for EBITDA Margin were 4125.32% (Q4 2025), 357.38% (Q3 2025), and 168.51% (Q2 2025) per Business Quant data.